Edwards Lifesciences’ EW fourth-quarter performance was backed by its most comprehensive structural heart disease portfolio. The Surgical Structural Heart business is benefiting from the strong ...

This was the stock's second consecutive day of losses.

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

Edwards Lifesciences Corporation (NYSE:EW) develops medical innovations for heart disease and critical care monitoring. Its ...

Q4 2024 Management View CEO Bernard Zovighian highlighted a strong Q4 2024 performance with total company sales growing 9% year-over-year to $1.39 billion and adjusted earnings per share of $0.59. He ...

Greenwich LifeSciences, Inc.'s main program, GLSI-100, faces challenges in proving its benefit over existing HER2-positive breast cancer treatments, with ongoing phase 3 trial results expected by ...

In its upcoming report, Edwards Lifesciences (EW) is predicted by Wall Street analysts to post quarterly earnings of $0.55 per share, reflecting a decline of 14.1% compared to the same period last ...

Zydus Lifesciences Ltd. reported US formulation sales that were ahead of expectations during the December quarter on Wednesday, February 5. Despite this, the stock has declined to the lows of the day.

Championship club Burnley are close to signing winger Marcus Edwards from Sporting Lisbon, talkSPORT understands. Edwards is set to join the Clarets on loan until the end of the 2024/25 season ...